Melanoma Medical Services in China

Melanoma is a malignant neoplasm arising from melanocytes—pigment-producing cells predominantly located in the epidermis, but also found in mucosal surfaces, uveal tract, and meninges. It accounts for the majority of skin cancer–related mortality despite representing only ~1% of all skin cancers. Key risk factors include ultraviolet radiation exposure, fair skin phenotype, numerous atypical nevi, and genetic predispositions such as CDKN2A mutations. Clinical presentation ranges from asymmetrical, irregularly pigmented lesions (ABCDE criteria) to amelanotic variants, with staging guided by Breslow thickness, ulceration status, mitotic rate, and nodal or distant metastasis (AJCC 8th edition). Management hinges on early surgical excision with appropriate margins; advanced cases may require sentinel lymph node biopsy, adjuvant immunotherapy (e.g., anti-PD-1 agents like pembrolizumab), targeted therapy (BRAF/MEK inhibitors for BRAF V600-mutated tumors), or radiotherapy. Prognosis correlates strongly with stage at diagnosis—5-year survival exceeds 99% for localized disease but drops to <30% in stage IV with visceral involvement.

China offers compelling advantages for melanoma care: Tier-1 oncology centers—including Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—host multidisciplinary melanoma tumor boards staffed by nationally recognized dermatologic oncologists, surgical oncologists, and molecular pathologists. These institutions utilize next-generation sequencing for comprehensive genomic profiling, digital dermoscopy with AI-assisted lesion analysis, and PET-CT/MRI fusion imaging for precise staging. Over 85% of stage III patients treated with combined immunotherapy regimens achieve progression-free survival beyond 24 months—comparable to U.S./EU benchmarks—while average treatment costs remain 40–60% lower than in Western countries, without compromising evidence-based protocols or regulatory compliance (NMPA-approved biologics and small molecules). As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying physician credentials, coordinating appointments across specialized departments, providing itemized, pre-authorized cost estimates, arranging visa support and local logistics, and assigning bilingual clinical liaisons for continuity of care—from initial consultation through follow-up.

Treatment Options & Itemized Cost Breakdown: Melanoma (Oncology Department)

Non-Surgical / Systemic Therapy Options

*Indicated for Stage III–IV unresectable/metastatic disease, adjuvant therapy post-resection, or inoperable primary lesions.*

• •BRAF/MEK Inhibitors (e.g., dabrafenib + trametinib)

- *Monthly cost:* ¥22,000–¥28,000 ($3,050–$3,880); 12-month adjuvant course: ¥264,000–¥336,000 ($36,600–$46,600) - *Monitoring:* Monthly LFTs/ECG (¥120; $17), q3mo CT/PET-CT (¥3,200; $445)

• •Immune Checkpoint Inhibitors

- *Ipilimumab + nivolumab combo:* ¥18,500/dose ($2,565); 4 doses → ¥74,000 ($10,270) - *Baseline labs (CBC, CMP, TSH, cortisol):* ¥380 ($53)

Surgical / Procedural Options

*All procedures performed in Oncology or General Surgery departments; no ophthalmic involvement.*

• •Wide Local Excision (WLE)

- *Procedure fee:* ¥4,800–¥7,500 ($665–$1,040); margin-dependent (1–2 cm) - *Pre-op workup:* Dermoscopy (¥150; $21), sentinel lymph node biopsy (SLNB) planning (¥600; $83), ECG + chest X-ray (¥220; $30)

• •Sentinel Lymph Node Biopsy (SLNB)

- *Fee:* ¥5,900–¥8,300 ($820–$1,150); includes radiocolloid injection, gamma probe guidance, intraoperative pathology - *Pre-op lymphoscintigraphy:* ¥1,400 ($195)

• •Completion Lymphadenectomy

- *Fee:* ¥12,600–¥16,800 ($1,750–$2,330); inguinal/axillary basin-specific

Special/Complex Condition Management

• •Brain Metastases (asymptomatic): Stereotactic radiosurgery (SRS) — ¥18,000–¥24,000 ($2,500–$3,330); includes MRI fusion planning
• •Leptomeningeal Disease: Intrathecal interleukin-2 (off-label) — ¥9,500/course ($1,320); requires lumbar puncture + CSF cytology (¥420; $58)
• •BRAF wild-type advanced disease: Anti-CTLA-4 + anti-PD-1 combo — ¥92,000 ($12,770) for full induction

Quick Selection Guide

• •<60 years, Stage II, no comorbidities: WLE + SLNB (Total: ¥12,000–¥17,000 / $1,665–$2,360)
• •Stage III, BRAF-mutated, budget >¥300,000: Adjuvant dabrafenib/trametinib (optimal recurrence reduction)
• •Stage IV, BRAF wild-type, limited metastases: Anti-PD-1 monotherapy + SRS for oligo-brain mets (Total Year 1: ¥145,000 / $20,100)
• •>75 years, multiple comorbidities, Stage IIIB: WLE only (no SLNB); avoid systemic therapy unless performance status ≥ECOG 0–1
• •Low-income patients (medical insurance coverage): First-line anti-PD-1 (toripalimab) covered at 60–70% subsidy; out-of-pocket ~¥35,000 ($4,850) for induction